MAKERSL177.20

Makers Laboratories Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOC
Comp Set
In ₹ Crore except Per Share
Latest Annual
MAKERSL
FY26
BPLPHARMA
FY23
JENBURPH
FY26
KPL
FY24
Peer
Median
Valuation — at last close
P/E37.02×37.02×
Growth
Revenue CAGR 3Y5.77%7.26%7.26% -21%
Revenue CAGR 5Y1.55%9.07%9.07% -83%
Net Income CAGR 3Y12.18%12.18%
Profitability
EBITDA Margin1.45%9.80%23.81%21.69%21.69% -93%
Net Income Margin-3.42%11.16%20.59%15.88% -122%
Return on Common Equity-3.16%12.74%12.74% -125%
Return on Capital Employed19.18%19.18%
Return on Assets-2.34%7.90%15.37%11.63% -120%
Credit & Quality
Total Debt/Equity0.05×0.04×0.43×0.23× -79%
Interest Coverage-3.91×7.10×4.54×5.82× -167%
Scale — latest FY
Revenue / Total Income₹50.3 Cr₹218 Cr₹169 Cr₹307 Cr₹218 Cr -77%
Net Income−₹1.7 Cr₹24.3 Cr₹34.7 Cr₹29.5 Cr -106%
Total Assets₹73.5 Cr₹308 Cr₹226 Cr₹398 Cr₹308 Cr -76%
EPS₹-2.91₹42.14₹42.14 -107%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.